Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 254

1.

PANCREATIC SAFETY IN STUDIES OF THE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST ALBIGLUTIDE.

Al-Kawas F, Anderson MA, Enns R, Wilson TH, Johnson S, Mallory JM.

Endocr Pract. 2019 Jul;25(7):698-716. doi: 10.4158/EP-2018-0507. Epub 2019 Mar 13.

PMID:
30865522
2.
3.

Albiglutide efficacy and safety in the Latino/Hispanic subpopulation for the integrated phase III program.

Davidson JA, Jones-Leone A, Wilson TH, Nino A, Forero-Schwanhaeuser S, Reinhardt RR.

Postgrad Med. 2017 Nov;129(8):849-857. doi: 10.1080/00325481.2017.1387473. Epub 2017 Oct 30.

PMID:
29083275
4.

A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).

Roehrborn CG, Manyak MJ, Palacios-Moreno JM, Wilson TH, Roos EPM, Santos JC, Karanastasis D, Plastino J, Giuliano F, Rosen RC.

BJU Int. 2018 Apr;121(4):647-658. doi: 10.1111/bju.14057. Epub 2017 Nov 16.

5.

Weekly glucagon-like peptide-1 receptor agonist albiglutide as monotherapy improves glycemic parameters in Japanese patients with type 2 diabetes mellitus: A randomized, double-blind, placebo-controlled study.

Nino A, Okuda I, Wilson TH, Yue L, Nakajima H, Tsuboi M, Carr MC, Seino Y.

J Diabetes Investig. 2017 Sep 16. doi: 10.1111/jdi.12749. [Epub ahead of print]

6.

Albiglutide, a weekly GLP-1 receptor agonist, improves glycemic parameters in Japanese patients with type 2 diabetes over 1 year when added to single oral antidiabetic drugs.

Okuda I, Wilson TH, Yue L, Nakajima H, Carr MC, Tsuboi M, Nino A, Seino Y.

Curr Med Res Opin. 2017 Mar;33(3):431-438. doi: 10.1080/03007995.2016.1261817. Epub 2016 Dec 21.

PMID:
27852119
7.

Gastrointestinal safety across the albiglutide development programme.

Leiter LA, Mallory JM, Wilson TH, Reinhardt RR.

Diabetes Obes Metab. 2016 Sep;18(9):930-5. doi: 10.1111/dom.12679. Epub 2016 May 31.

PMID:
27097971
8.

Modeling and analysis of Gleason score 8-10 prostate cancers in the REDUCE study.

Andriole GL, Bostwick DG, Gomella LG, Marberger M, Montorsi F, Tammela TL, Tindall DJ, Fowler IL, Garges HP, Wilson TH, Castro R.

Urology. 2014 Aug;84(2):393-9. doi: 10.1016/j.urology.2014.04.016. Epub 2014 Jun 7.

PMID:
24916669
9.

Impact of dutasteride on nocturia in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia (LUTS/BPH): a pooled analysis of three phase III studies.

Oelke M, Roehrborn CG, D'Ancona C, Wilson TH, Castro R, Manyak M.

World J Urol. 2014 Oct;32(5):1141-7. doi: 10.1007/s00345-014-1316-3. Epub 2014 Jun 6.

PMID:
24903347
10.

Nocturia improvement in the combination of Avodart(®) and tamsulosin (CombAT) study.

Oelke M, Roehrborn CG, D'Ancona C, Wilson TH, Castro R, Manyak M.

World J Urol. 2014 Oct;32(5):1133-40. doi: 10.1007/s00345-014-1296-3. Epub 2014 May 8.

PMID:
24804842
12.

Predictors of pathological progression among men with localized prostate cancer undergoing active surveillance: a sub-analysis of the REDEEM study.

Margel D, Nandy I, Wilson TH, Castro R, Fleshner N.

J Urol. 2013 Dec;190(6):2039-45. doi: 10.1016/j.juro.2013.06.051. Epub 2013 Jun 29.

PMID:
23820059
13.

The effect of dutasteride on the detection of prostate cancer: A set of meta-analyses.

Monga N, Sayani A, Rubinger DA, Wilson TH, Su Z.

Can Urol Assoc J. 2013 Mar-Apr;7(3-4):E161-7. doi: 10.5489/cuaj.477.

14.

Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study.

Chung BH, Lee SH, Roehrborn CG, Siami PF, Major-Walker K, Wilson TH, Montorsi F; CombAT Study Group.

Int J Urol. 2012 Nov;19(11):1031-5. doi: 10.1111/j.1442-2042.2012.03091.x. Epub 2012 Jul 9.

15.

Quantifying the contribution of symptom improvement to satisfaction of men with moderate to severe benign prostatic hyperplasia: 4-year data from the CombAT trial.

Roehrborn CG, Wilson TH, Black LK.

J Urol. 2012 May;187(5):1732-8. doi: 10.1016/j.juro.2011.12.083. Epub 2012 Mar 15.

PMID:
22425127
16.

Dutasteride reduces prostatitis symptoms compared with placebo in men enrolled in the REDUCE study.

Nickel JC, Roehrborn C, Montorsi F, Wilson TH, Rittmaster RS.

J Urol. 2011 Oct;186(4):1313-8. doi: 10.1016/j.juro.2011.05.071. Epub 2011 Aug 17.

PMID:
21849186
17.

Dutasteride improves outcomes of benign prostatic hyperplasia when evaluated for prostate cancer risk reduction: secondary analysis of the REduction by DUtasteride of prostate Cancer Events (REDUCE) trial.

Roehrborn CG, Nickel JC, Andriole GL, Gagnier RP, Black L, Wilson TH, Rittmaster RS.

Urology. 2011 Sep;78(3):641-6. doi: 10.1016/j.urology.2011.03.063. Epub 2011 Jul 20.

PMID:
21764428
18.

Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS).

Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS.

BJU Int. 2011 Aug;108(3):388-94. doi: 10.1111/j.1464-410X.2011.10195.x. Epub 2011 Jun 1.

19.

The effects of dutasteride or tamsulosin alone and in combination on storage and voiding symptoms in men with lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH): 4-year data from the Combination of Avodart and Tamsulosin (CombAT) study.

Montorsi F, Roehrborn C, Garcia-Penit J, Borre M, Roeleveld TA, Alimi JC, Gagnier P, Wilson TH.

BJU Int. 2011 May;107(9):1426-31. doi: 10.1111/j.1464-410X.2011.10129.x. Epub 2011 Feb 23.

20.
21.

Effect of dutasteride on prostate biopsy rates and the diagnosis of prostate cancer in men with lower urinary tract symptoms and enlarged prostates in the Combination of Avodart and Tamsulosin trial.

Roehrborn CG, Andriole GL, Wilson TH, Castro R, Rittmaster RS.

Eur Urol. 2011 Feb;59(2):244-9. doi: 10.1016/j.eururo.2010.10.040. Epub 2010 Nov 4.

PMID:
21093145
22.

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study.

Andriole GL, Bostwick D, Brawley OW, Gomella L, Marberger M, Montorsi F, Pettaway C, Tammela TL, Teloken C, Tindall D, Freedland SJ, Somerville MC, Wilson TH, Fowler I, Castro R, Rittmaster RS; REDUCE Study Group.

J Urol. 2011 Jan;185(1):126-31. doi: 10.1016/j.juro.2010.09.011. Epub 2010 Nov 12.

PMID:
21074214
23.

Low serum testosterone levels are poor predictors of sexual dysfunction.

Marberger M, Wilson TH, Rittmaster RS.

BJU Int. 2011 Jul;108(2):256-62. doi: 10.1111/j.1464-410X.2010.09766.x. Epub 2010 Oct 18.

24.

Effect of dutasteride on the risk of prostate cancer.

Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, Fowler IL, Rittmaster RS; REDUCE Study Group.

N Engl J Med. 2010 Apr 1;362(13):1192-202. doi: 10.1056/NEJMoa0908127.

25.

The effects of dutasteride, tamsulosin, and the combination on storage and voiding in men with benign prostatic hyperplasia and prostatic enlargement: 2-year results from the Combination of Avodart and Tamsulosin study.

Becher E, Roehrborn CG, Siami P, Gagnier RP, Wilson TH, Montorsi F.

Prostate Cancer Prostatic Dis. 2009;12(4):369-74. doi: 10.1038/pcan.2009.37. Epub 2009 Sep 1.

PMID:
19901936
26.

Efficacy and safety of dutasteride, tamsulosin and their combination in a subpopulation of the CombAT study: 2-year results in Asian men with moderate-to-severe BPH.

Chung BH, Roehrborn CG, Siami P, Major-Walker K, Morrill BB, Wilson TH, Montorsi F.

Prostate Cancer Prostatic Dis. 2009;12(2):152-9. doi: 10.1038/pcan.2008.49. Epub 2008 Sep 23.

PMID:
18813219
27.
28.

Marked suppression of dihydrotestosterone in men with benign prostatic hyperplasia by dutasteride, a dual 5alpha-reductase inhibitor.

Clark RV, Hermann DJ, Cunningham GR, Wilson TH, Morrill BB, Hobbs S.

J Clin Endocrinol Metab. 2004 May;89(5):2179-84.

PMID:
15126539
29.

Transport of L-Lactate, D-Lactate, and glycolate by the LldP and GlcA membrane carriers of Escherichia coli.

Núñez MF, Kwon O, Wilson TH, Aguilar J, Baldoma L, Lin EC.

Biochem Biophys Res Commun. 2002 Jan 18;290(2):824-9.

PMID:
11785976
30.
31.

Cysteine substitutions for individual residues in helix VI of the melibiose carrier of Escherichia coli.

Ding PZ, Weissborn AC, Wilson TH.

J Membr Biol. 2001 Sep 1;183(1):33-8.

PMID:
11547350
32.
33.

Regulation of galactoside transport by the PTS.

Kuroda M, Wilson TH, Tsuchiya T.

J Mol Microbiol Biotechnol. 2001 Jul;3(3):381-4. Review.

PMID:
11361068
34.

Physiological evidence for an interaction between helices II and XI in the melibiose carrier of Escherichia coli.

Franco PJ, Jena AB, Wilson TH.

Biochim Biophys Acta. 2001 Feb 9;1510(1-2):231-42.

35.
36.

Sodium-substrate cotransport in bacteria.

Wilson TH, Ding PZ.

Biochim Biophys Acta. 2001 May 1;1505(1):121-30. Review.

37.

OSHA's ergonomic standard in the health care workplace.

Wilson TH.

Contemp Longterm Care. 2001 Feb;24(2):15-6. No abstract available.

PMID:
11216067
39.

Mutants of the lactose carrier of Escherichia coli which show altered sugar recognition plus a severe defect in sugar accumulation.

Varela MF, Wilson TH, Rodon-Rivera V, Shepherd S, Dehne TA, Rector AC.

J Membr Biol. 2000 Apr 1;174(3):199-205.

PMID:
10758173
40.
41.
43.

Melibiose carrier of Escherichia coli: use of cysteine mutagenesis to identify the amino acids on the hydrophilic face of transmembrane helix 2.

Matsuzaki S, Weissborn AC, Tamai E, Tsuchiya T, Wilson TH.

Biochim Biophys Acta. 1999 Aug 20;1420(1-2):63-72.

44.

Mutants of Citrobacter freundii that transport and utilize melibiose.

Okazaki N, Xu XJ, Shimamoto T, Kuroda M, Wilson TH, Tsuchiya T.

J Bacteriol. 1998 Jul;180(13):3480-2.

45.

The construction of a cysteine-less melibiose carrier from E. coli.

Weissborn AC, Botfield MC, Kuroda M, Tsuchiya T, Wilson TH.

Biochim Biophys Acta. 1997 Oct 23;1329(2):237-44.

46.
47.

Molecular biology of the lactose carrier of Escherichia coli.

Varela MF, Wilson TH.

Biochim Biophys Acta. 1996 Aug 7;1276(1):21-34. Review. No abstract available.

48.
49.

Chemostat selection of an Escherichia coli mutant containing permease with enhanced lactose affinity.

Tsen SD, Lai SC, Pang CP, Lee JI, Wilson TH.

Biochem Biophys Res Commun. 1996 Jul 16;224(2):351-7.

PMID:
8702394
50.

Supplemental Content

Loading ...
Support Center